PIQRAY® Effective after Progression on CDK Inhibition in Advanced Breast Cancer
Overall Survival Benefit with Frontline OPDIVO® plus YERVOY® and Limited Chemotherapy in NSCLC
Late Breaking Abstract – ASCO 2020: Local Therapy Does Not Extend Survival in Newly Diagnosed Metastatic Breast Cancer
Late Breaking Abstract – ASCO 2020: FDA Approves BAVENCIO® for Maintenance Treatment in Advanced Urothelial Carcinoma
Late Breaking Abstract – ASCO 2020: Adjuvant Therapy with TAGRISSO® Improves Survival in Early Stage EGFR-Mutated Non Small Cell Lung Cancer
KEYTRUDA® Superior to ADCETRIS® in Relapsed or Refractory Classical Hodgkin Lymphoma
Late Breaking Abstract – ASCO 2020: First Line KEYTRUDA® Superior to Chemotherapy in Metastatic MSI-H/dMMR Colorectal Cancer
FDA Approves RETEVMO® for RET Altered Non Small Cell Lung Cancer and Thyroid Cancers
Oral Relugolix Superior to Leuprolide in Advanced Prostate Cancer
FDA Approves CYRAMZA® Plus TARCEVA® for EGFR Mutated NSCLC
FDA Approves TECENTRIQ® in Combination with AVASTIN® for Hepatocellular Carcinoma
COVID-19 Associated Coagulopathy: Diagnosis and Management
Dietary Supplement Use during Adjuvant Chemotherapy May Increase Risk for Breast Cancer Recurrence
FDA Approves ALUNBRIG® for First Line Treatment of ALK Positive Non Small Cell Lung Cancer
FDA Approves Chemotherapy-Free First Line Immunotherapy Combination in Advanced NSCLC
FDA Approves RUBRACA® for BRCA-Mutated Metastatic Castrate Resistant Prostate Cancer
FDA Approves TABRECTA® for Metastatic Non-Small Cell Lung Cancer
Proton Based Chemoradiotherapy Significantly Decreases Toxicities without Compromising Efficacy
FDA Approves ZEJULA® for Newly Diagnosed Patients with Advanced Ovarian Cancer
FDA Approves Subcutaneous DARZALEX® in Multiple Myeloma
Bottom Ad
Advertisement
Subscribe
